Patient | Age yrs | Sex | Ethnic origin | Country of birth | Clinical diagnosis | TST mm | MTB culture | MTB-NAT | Lymphocytes in PE % | ESAT-6 PBMCs | CFP-10 PBMCs | ELISPOT test result blood | ESAT-6 PEMCs | CFP-10 PEMCs | ELISPOT test result pleural fluid |
1 | 62 | F | Caucasian | Germany | Pleural TB | 0 | +ve | -ve | 94 | 79 (83–4) | 27 (31–4) | +ve | 141 (142–1) | 49 (50–1) | +ve |
2 | 55 | F | Caucasian | Germany | Pleural TB | 0 | +ve | +ve | 94 | 4 (4–0) | 27 (27–0) | +ve | 25 (25–0) | 60 (60–0) | +ve |
3 | 27 | F | Caucasian | Germany | Pleural TB | ND | +ve | -ve | 77 | 11 (13–2) | 23 (25–2) | +ve | 68 (68–0) | 136 (136–0) | +ve |
4 | 34 | F | Black | Somalia | Pleural TB Pericardial TB | ND | +ve | +ve | 94 | 40 (40–0) | 62 (62–0) | +ve | 255 (255–0) | 375 (375–0) | +ve |
5 | 25 | M | Caucasian | Morocco | Pleural TB | ND | +ve | -ve | 95 | 36 (36–0) | 18 (18–0) | +ve | 48 (48–0) | 29 (29–0) | +ve |
6 | 52 | M | Caucasian | Netherlands | Pleural TB Pericardial TB | 12 | +ve | -ve | 50 | 26 (26–0) | 20 (20–0) | +ve | 33 (33–0) | 49 (49–0) | +ve |
7 | 27 | M | Asian | India | Pleural and pulmonary TB | 12 | +ve | -ve | 87 | 4 (6–2) | 14 (16–2) | +ve | 13 (21–8) | 16 (24–8) | +ve |
8 | 76 | M | Caucasian | Italy | Pleural TB | 0 | +ve | NA | 13 | 0 (0–0) | 24 (24–0) | +ve | 54 (54–0) | 193 (193–0) | +ve |
9 | 43 | F | Caucasian | Netherlands | Pleural TB | ND | -ve | +ve | 83 | 23 (23–0) | 60 (60–0) | +ve | >400 (>400–0) | >400 (>400–0) | +ve |
10 | 22 | F | Caucasian | Netherlands | Pleural TB | ND | -ve | +ve | NA | 21 (21–0) | 26 (26–0) | +ve | >400 (>400–0) | >400 (>400–0) | +ve |
11 | 37 | M | Caucasian | Netherlands | Presumed pleural TB and Pericardial TB | ND | -ve | -ve | 60 | 38 (38–0) | 150 (150–0) | +ve | >400 (>400–50) | >400 (>400–50) | +ve |
12 | 23 | M | Caucasian | Morocco | Presumed pleural TB | ND | -ve | -ve | 95 | 16 (16–0) | 33 (33–0) | +ve | >400 (>400–0) | >400 (>400–0) | +ve |
13 | 53 | M | Black | Ethiopia | Presumed pleural TB | 24 | -ve | -ve | 16 | 12 (12–0) | 15 (15–0) | +ive | 280 (281–1) | 189 (190–1) | +ve |
14 | 28 | F | Hispanic | Peru | Presumed pleural TB | 23 | -ve | -ve | 95 | 12 (13–1) | 5 (6–1) | +ve | 193 (193–0) | 131 (131–0) | +ve |
15 | 21 | M | Caucasian | Italy | Presumed pleural TB | 17 | -ve | -ve | 44 | 60 (61–1) | 66 (67–19 | +ve | 207 (275–68) | 202 (270–68) | +ve |
16 | 27 | M | Black | Erithrea | Presumed pleural TB | 0 | -ve | -ve | 39 | 58 (58–0) | 0 (0–0) | +ve | 207 (207–0) | 40 (40–0) | +ve |
17 | 72 | M | Caucasian | Italy | Presumed pleural TB | 0 | -ve | -ve | 75 | 84 (88–4) | 4 (8–4) | +ve | 192 (200–8) | 7 (15–8) | +ve |
18 | 33 | M | Asian | India | Presumed pleural TB | 10 | -ve | -ve | 85 | 31 (32–1) | 38 (39–1) | +ve | 50 (51–1) | 154 (155–1) | +ve |
19 | 35 | M | Caucasian | Italy | Presumed pleural TB | 0 | -ve | -ve | 88 | 0 (0–0) | 0 (0–0) | -ve | 23 (23–0) | 11 (11–0) | +ve |
20 | 40 | M | Black | Ecuador | Presumed pleural TB | 20 | -ve | -ve | 82 | 0 (3–6) | 0 (4–6) | -ve | 2 (2–0) | 4 (4–0) | -ve |
21 | 73 | M | Caucasian | Germany | NSCLC | 16 | -ve | -ve | 43 | 35 (35–0) | 118 (118–0) | +ve | 98 (98–0) | 85 (85–0) | +ve |
22 | 41 | F | Caucasian | Germany | Exudative pleurisy | 3 | -ve | -ve | 95 | 0 (0–3) | 0 (0–3) | -ve | 12 (18–6) | 15 (21–6) | +ve |
23 | 71 | M | Caucasian | Germany | Fib. fibroblastic pleurisy | 0 | -ve | -ve | 90 | 2 (2–0) | 1 (1–0) | -ve | 2 (3–1) | 3 (4–1) | -ve |
24 | 84 | M | Caucasian | Germany | Exudative pleurisy | ND | -ve | -ve | 1.3 | 4 (5–1) | 5 (6–1) | -ve | 0 (0–0) | 0 (0–0) | -ve |
25 | 27 | M | Caucasian | Poland | Fib. fibroblastic pleurisy | 18 | -ve | -ve | 19 | 3 (3–0) | 6 (6–0) | +ve | 5 (6–1) | 1 (2–1) | -ve |
26 | 85 | M | Caucasian | Germany | NSCLC | 0 | -ve | -ve | 99 | 1 (2–1) | 0 (1–1) | -ve | 2 (2–0) | 2 (2–0) | -ve |
27 | 65 | M | Caucasian | Germany | Exudative pleurisy | 0 | -ve | -ve | 5 | 0 (0–2) | 0 (0–2) | -ve | 1 (1–0) | 0 (0–0) | -ve |
28 | 44 | M | Caucasian | Germany | Fib. fibroblastic pleurisy | 0 | -ve | -ve | 92 | 4 (4–0) | 3 (3–0) | -ve | 0 (0–0) | 0 (0–0) | -ve |
29 | 67 | M | Caucasian | Germany | RA | 0 | -ve | -ve | 92 | 6 (6–0) | 7 (7–0) | +ve | 0 (1–3) | 0 (2–3) | -ve |
30 | 92 | M | Caucasian | Italy | NSCLC | 0 | -ve | -ve | 90 | 14 (15–1) | 7 (8–1) | +ve | 0 (0–0) | 1 (1–0) | -ve |
31 | 25 | F | Caucasian | Moldova | Interstitial lung disease | 10 | -ve | -ve | 20 | 2 (3–1) | 3 (4–1) | -ve | 0 (5–11) | 0 (5–11) | -ve |
32 | 84 | F | Caucasian | Italy | Breast cancer | 0 | -ve | -ve | 87 | 0 (0–0) | 4 (4–0) | -ve | 0 (0–2) | 0 (0–2) | -ve |
33 | 76 | M | Caucasian | Italy | Exudative pleurisy | 0 | -ve | -ve | 95 | 0 (0–2) | 0 (0–2) | -ve | 0 (0–0) | 1 (1–0) | -ve |
34 | 66 | M | Caucasian | Italy | Mesothelioma | 0 | -ve | -ve | 15 | 1 (1–0) | 2 (2–0) | -ve | 4 (11–7) | 3 (10–7) | -ve |
35 | 77 | M | Caucasian | Italy | NSCLC | 0 | -ve | -ve | 92 | 2 (2–0) | 1 (1–0) | -ve | 0 (5–10) | 1 (11–10) | -ve |
36 | 41 | F | Caucasian | Poland | Exudative pleurisy | 0 | -ve | -ve | 90 | 0 (0–0) | 0 (0–0) | -ve | 2 (2–0) | 0 (0–0) | -ve |
37 | 80 | F | Caucasian | Italy | Lymphoma (history of TB) | 10 | -ve | -ve | 70 | 8 (9–1) | 3 (4–1) | +ve | 63 (66–3) | 58 (61–3) | +ve |
38 | 85 | M | Caucasian | Italy | Exudative pleurisy | 0 | -ve | -ve | 70 | 0 (0–0) | 62 (62–0) | +ve | 5 (5–0) | 132 (132–0) | +ve |
39 | 32 | F | Caucasian | Italy | Mesothelioma | 0 | -ve | -ve | 93 | 2 (6–4) | 2 (6–4) | -ve | 0 (0–0) | 0 (0–0) | -ve |
40 | 71 | M | Caucasian | Italy | Exudative pleurisy | ND | -ve | -ve | 76 | 4 (5–1) | 3 (4–1) | -ve | 1 (1–0) | 0 (0–0) | -ve |
41 | 68 | M | Caucasian | Italy | Exudative pleurisy | 12 | -ve | -ve | 91 | 32 (32–0) | 0 (0–0) | +ve | 42 (48–6) | 4 (10–6) | +ve |